Back to Report Store Home

Global Cardiovascular Disease Drugs Market to 2023 – Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

  • Published: Dec-2017
  • Report Code: GBIHC461MR
  • Report Format: pdf

Description

List of Tables

Table 1: Cardiovascular Disease Drugs Market, US, Systolic and Diastolic Blood Pressure Level and Corresponding Category, 2017 13

Table 2: Cardiovascular Disease Drugs Market, Global, Total Cholesterol, LDL and HDL Levels and Corresponding Category, 2017 14

Table 3: Cardiovascular Disease Drugs Market, Global, Approved Indications for Lipitor, 2017 38

Table 4: Cardiovascular Disease Drugs Market, Global, Approved Indications for Crestor, 2017 39

Table 5: Cardiovascular Disease Drugs Market, Global, Approved Indications for Zetia, 2017 41

Table 6: Cardiovascular Disease Drugs Market, Global, Approved Indications for Praluent, 2017 42

Table 7: Cardiovascular Disease Drugs Market, Global, Approved Indications for Repatha, 2017 43

Table 8: Cardiovascular Disease Drugs Market, Global, Approved Indications for Plavix, 2017 44

Table 9: Cardiovascular Disease Drugs Market, Global, Approved Indications for Xarelto, 2017 46

Table 10: Cardiovascular Disease Drugs Market, Global, Approved Indications for Eliquis, 2017 47

Table 11: Cardiovascular Disease Drugs Market, Global, Approved Indications for Brilinta, 2017 49

Table 12: Cardiovascular Disease Drugs Market, Global, Approved Indications for Entresto, 2017 50

Table 13: Cardiovascular Disease Drugs Market, Global, Approved Indications for Benicar, 2017 51

Table 14: Cardiovascular Disease Drugs Market, Global, Approved Indications for Bevyxxa, 2017 52

Table 15: Cardiovascular Disease Drugs Market, Global, Approved Indications for Uptravi, 2017 54

Table 16: Cardiovascular Disease Drugs Market, Global, Approved Indications for Opsumit, 2017 55

Table 17: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Inclisiran, 2017 84

Table 18: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for MEDI-6012, 2017 86

Table 19: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Volanesorsen Sodium, 2017 88

Table 20: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Vericiguat, 2017 90

Table 21: Cardiovascular Disease Drugs Market, Global, Clinical Evidence for Bempedoic Acid, 2017 92

Table 22: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023 (part 1) 96

Table 23: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023 (part 2) 97

Table 24: Cardiovascular Disease Drugs Market, Global, Usage of Generics Across Key Indications, 2017 101

Table 25: Cardiovascular Disease Drugs Market, Global, Forecast Revenues by Company, 2016–2023 113

Table 26: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Discovery, 2017 146

Table 27: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Preclinical, 2017 157

Table 28: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2017 200

Table 29: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase I, 2017 201

Table 30: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase II, 2017 206

Table 31: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase III, 2017 214

Table 32: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017 221

Table 33: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Unknown, 2017 223

Table 34: Abbreviations 224

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards